Experts from Columbia University highlight approvals in CLL, bispecific antibodies in multiple myeloma, and actionable biomarkers in DLBCL.
Rajshekhar Chakraborty, MD
Advertisement
Articles by Rajshekhar Chakraborty, MD
Education, REMS certification, and long-term management are key barriers to the widespread adoption of bispecific antibodies in the community setting.
Advertisement
Latest Updated Articles
Insights Across Hematologic Oncology at Columbia UniversityMarch 16th 2026
Advertisement
Advertisement
Trending on CancerNetwork
1
A Brief History of Major Events in Oncology
2
Top 3 Insights on Locoregional Recurrence in Young-Onset Breast Cancer
3
Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus–Positive DLBCL: A Rare Concomitant Association
4
This Week in Oncology: Real-World NSCLC Care and AACR 2026 Updates
5